Cytospire Therapeutics oversubscribed £61M ($83m) Series A financing to advance pan-gamma delta T cell engagers into clinical trials for the treatment of cancer
“We are excited to write the next chapter of Cytospire’s story with this fantastic group of specialist investors,” said Natalie Mount, Chief Executive Officer of Cytospire Therapeutics. “Immune cell engagers are an important type of cancer immunotherapy, but we know that there are significant limitations from both an efficacy and safety perspective with conventional CD3 T cell engagers. We are building on the growing body of translational and clinical data showing gamma delta T cells are critical components of the anti-cancer immune response, with biology ideally suited to novel cell engagers. The significant fundraise that we are announcing today reflects the quality of our team and our science, and the huge potential of our pan-gamma delta T cell engagers”.
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines